Loading...

Homology Medicines

DB:35H
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
35H
DB
$948M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Homology Medicines has significant price volatility in the past 3 months.
35H Share Price and Events
7 Day Returns
3.1%
DB:35H
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
22.1%
DB:35H
-7.4%
DE Biotechs
-5.6%
DE Market
35H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Homology Medicines (35H) 3.1% -9.5% 8.9% 22.1% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 35H outperformed the Biotechs industry which returned -7.4% over the past year.
  • 35H outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Homology Medicines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Homology Medicines. This is due to cash flow or dividend data being unavailable. The share price is €20.545.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Homology Medicines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Homology Medicines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:35H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.00
NasdaqGS:FIXX Share Price ** NasdaqGS (2019-04-24) in USD $22.08
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Homology Medicines.

DB:35H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FIXX Share Price ÷ EPS (both in USD)

= 22.08 ÷ -2.00

-11.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Homology Medicines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Homology Medicines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Homology Medicines's expected growth come at a high price?
Raw Data
DB:35H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-11.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Homology Medicines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Homology Medicines's assets?
Raw Data
DB:35H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $5.21
NasdaqGS:FIXX Share Price * NasdaqGS (2019-04-24) in USD $22.08
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:35H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FIXX Share Price ÷ Book Value per Share (both in USD)

= 22.08 ÷ 5.21

4.24x

* Primary Listing of Homology Medicines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Homology Medicines is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Homology Medicines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Homology Medicines has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Homology Medicines expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-11.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Homology Medicines expected to grow at an attractive rate?
  • Unable to compare Homology Medicines's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Homology Medicines's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Homology Medicines's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:35H Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:35H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -11.2%
DB:35H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 47.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:35H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:35H Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 52 -42 -105 2
2022-12-31 25 -82 -114 2
2021-12-31 7 -116 -119 2
2020-12-31 9 -91 -102 4
2019-12-31 4 -81 -86 3
DB:35H Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -43 -57
2018-09-30 3 -12 -50
2018-06-30 2 -4 -42
2018-03-31 1 0 -35
2017-12-31 6 -30
2016-12-31 -8 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Homology Medicines is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Homology Medicines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:35H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Homology Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:35H Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.04 -0.78 -3.30 2.00
2022-12-31 -2.31 -1.62 -3.00 2.00
2021-12-31 -2.68 -2.36 -3.00 2.00
2020-12-31 -2.27 -2.03 -2.45 4.00
2019-12-31 -2.21 -2.11 -2.25 4.00
DB:35H Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.00
2018-09-30 -2.50
2018-06-30 -3.77
2018-03-31 -13.41
2017-12-31 -12.10
2016-12-31 -4.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Homology Medicines will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Homology Medicines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Homology Medicines has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Homology Medicines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Homology Medicines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Homology Medicines does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Homology Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Homology Medicines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Homology Medicines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Homology Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:35H Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.68 -57.22 17.30
2018-09-30 2.70 -50.12 14.90 21.38
2018-06-30 1.75 -41.85 12.76 21.38
2018-03-31 0.82 -34.96 10.21 21.38
2017-12-31 -29.99 8.28
2016-12-31 -8.05 4.31 5.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Homology Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Homology Medicines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Homology Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Homology Medicines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Homology Medicines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Homology Medicines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Homology Medicines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Homology Medicines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Homology Medicines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Homology Medicines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Homology Medicines has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Homology Medicines Company Filings, last reported 3 months ago.

DB:35H Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 194.72 0.00 214.74
2018-09-30 212.76 0.00 237.54
2018-06-30 226.80 0.00 255.51
2018-03-31 88.24 0.00 116.73
2017-12-31 98.31 0.00 129.66
2016-12-31 11.75 0.00 11.39
  • Homology Medicines has no debt.
  • Homology Medicines has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Homology Medicines has sufficient cash runway for more than 3 years based on current free cash flow.
  • Homology Medicines has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 108.1% each year.
X
Financial health checks
We assess Homology Medicines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Homology Medicines has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Homology Medicines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Homology Medicines dividends. Estimated to be 0% next year.
If you bought €2,000 of Homology Medicines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Homology Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Homology Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:35H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:35H Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Homology Medicines has not reported any payouts.
  • Unable to verify if Homology Medicines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Homology Medicines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Homology Medicines has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Homology Medicines's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Homology Medicines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Homology Medicines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Homology Medicines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Homology Medicines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Arthur Tzianabos
COMPENSATION $4,313,115
AGE 55
TENURE AS CEO 3 years
CEO Bio

Dr. Arthur O. Tzianabos, Ph.D., has been the Chief Executive Officer, President and Director of Homology Medicines, Inc. since April 2016. Dr. Tzianabos served as the President and Chief Scientific Officer at OvaScience, Inc. from September of 2013 to March of 2016. Dr. Tzianabos served as the Chief Scientific Officer of OvaScience, Inc. from July 2013 to March 31, 2016. Dr. Tzianabos served as Vice President of Program Management, Head of Research and Early Development and Senior Vice President at Shire plc. He has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. During his eight years at Shire, he served in roles of increasing responsibility and was instrumental in the development of the human genetic therapies pipeline following Shire's acquisition of Transkaryotic Therapies, Inc. in 2005. Dr. Tzianabos joined Shire in 2005 as Senior Director, Discovery Research and was instrumental in establishing the Discovery Research group and played a leading role in the expansion of Shire HGT research pipeline shortly after the acquisition of TKT by Shire. He serves as Chair of Scientific Advisory Board at OvaScience, Inc. He has been a Member of Scientific Advisory Board at Agilis Biotherapeutics, LLC since June 2014 and as its Director since September 2015. He served as Director of ArmaGen Technologies, Inc. since December 2012. He served as a Director of bluebird bio. Prior to Shire, Dr. Tzianabos served as an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. His research at Harvard led to the discovery of a new class of immunoregulatory, T cell-dependent antigens, which formed the basis for technologies licensed by two biotechnology companies and Eli Lilly and Company for clinical development. During his time at Harvard, he served as a Consultant to several biotechnology companies, including Genzyme Corporation and Eli Lilly. He has been a Director of BIND Therapeutics, Inc. since October 2015. He served as a Director of DNIB Unwind, Inc. since October 2015. Dr. Tzianabos has published more than 80 scientific papers, book chapters and patents in the field of immunology, glycobiology and infectious disease. He holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.

CEO Compensation
  • Arthur's compensation has increased whilst company is loss making.
  • Arthur's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Homology Medicines management team in years:

3
Average Tenure
54
Average Age
  • The tenure for the Homology Medicines management team is about average.
Management Team

Arthur Tzianabos

TITLE
President
COMPENSATION
$4M
AGE
55
TENURE
3 yrs

Tim Kelly

TITLE
Chief Technical Operations Officer
COMPENSATION
$2M
AGE
49
TENURE
1.9 yrs

Albert Seymour

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
50
TENURE
3 yrs

Saswati Chatterjee

TITLE
Co-Founder & Chair of Scientific Advisory Board

Brad Smith

TITLE
CFO, Treasurer & Secretary
COMPENSATION
$683K
AGE
62
TENURE
2 yrs

Sam Rasty

TITLE
Chief Operating Officer
AGE
54
TENURE
3.1 yrs

Theresa McNeely

TITLE
Senior Vice President of Corporate Communications & Patient Advocacy
AGE
54

Cara Mayfield

TITLE
Director of Corporate Communications
Board of Directors Tenure

Average tenure and age of the Homology Medicines board of directors in years:

2.3
Average Tenure
56.5
Average Age
  • The average tenure for the Homology Medicines board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kush Parmar

TITLE
Chairman
COMPENSATION
$315K
AGE
37

Arthur Tzianabos

TITLE
President
COMPENSATION
$4M
AGE
55
TENURE
3 yrs

Saswati Chatterjee

TITLE
Co-Founder & Chair of Scientific Advisory Board

Cameron Wheeler

TITLE
Director
COMPENSATION
$286K
AGE
39
TENURE
2.3 yrs

Mary Thistle

TITLE
Director
COMPENSATION
$292K
AGE
58
TENURE
1.1 yrs

Richard Gregory

TITLE
Director
COMPENSATION
$291K
AGE
60
TENURE
4.3 yrs

Steve Gillis

TITLE
Director
COMPENSATION
$286K
AGE
65
TENURE
3.3 yrs

Mahendra Shah

TITLE
Director
COMPENSATION
$286K
AGE
73
TENURE
2.3 yrs

Matt Patterson

TITLE
Director
COMPENSATION
$190K
AGE
46
TENURE
1.3 yrs

Stephen Elledge

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Apr 19 Buy Deerfield Management Company, L.P. Company 12. Apr 19 12. Apr 19 533,333 €19.88 €10,604,393
13. Dec 18 Sell 5AM Venture Management LLC Company 10. Dec 18 10. Dec 18 -15,575 €22.88 €-356,304
27. Nov 18 Sell 5AM Venture Management LLC Company 23. Nov 18 23. Nov 18 -29,682 €17.67 €-524,592
20. Nov 18 Sell 5AM Venture Management LLC Company 16. Nov 18 16. Nov 18 -525,900 €17.71 €-9,315,467
X
Management checks
We assess Homology Medicines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Homology Medicines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Details
Name: Homology Medicines, Inc.
35H
Exchange: DB
Founded: 2015
$846,629,608
42,914,082
Website: http://www.homologymedicines.com
Address: Homology Medicines, Inc.
One Patriots Park,
Bedford,
Massachusetts, 01730,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FIXX Common Stock Nasdaq Global Select US USD 28. Mar 2018
DB 35H Common Stock Deutsche Boerse AG DE EUR 28. Mar 2018
LSE 0T6G Common Stock London Stock Exchange GB USD 28. Mar 2018
Number of employees
Current staff
Staff numbers
124
Homology Medicines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:37
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.